# A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels

Study · id `cardio:ct-nct01388816` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01388816](<https://clinicaltrials.gov/study/NCT01388816>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT01388816

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.

## Technical summary

Registry record NCT01388816. Randomized; quadruple masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2014-04-22.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 176 participants (enrolled count; ClinicalTrials.gov record NCT01388816, source copy `cardio:ctgov-nct01388816-2014-04-22`, retrieved 2026-11-18)
- Start date: 2011-07 (registry gives no type) (ClinicalTrials.gov record NCT01388816, source copy `cardio:ctgov-nct01388816-2014-04-22`, retrieved 2026-11-18)
- Primary completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01388816, source copy `cardio:ctgov-nct01388816-2014-04-22`, retrieved 2026-11-18)
- Completion: 2012-06 (actual) (ClinicalTrials.gov record NCT01388816, source copy `cardio:ctgov-nct01388816-2014-04-22`, retrieved 2026-11-18)
- Results first posted: 2014-04-22 (ClinicalTrials.gov record NCT01388816, source copy `cardio:ctgov-nct01388816-2014-04-22`, retrieved 2026-11-18)
- Countries: Italy; Poland; Ukraine (ClinicalTrials.gov record NCT01388816, source copy `cardio:ctgov-nct01388816-2014-04-22`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01388816-2014-04-22`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels
- Condition: Type II Hyperlipidemia
- Intervention (Drug): DRL-17822 or placebo
- Lead sponsor: Dr. Reddy's Laboratories Limited, India
- Lead sponsor class: INDUSTRY
- Collaborator: PharmaNet
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 24afa218eca39e0689e69b2a4360cecba842b068d8929aafb90ff261f9cb6de1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
